Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform

Posted : Wed, 04 Nov 2009 15:01:54 GMT
Author : Neuronascent, Inc.
Category : Press Release
News Alerts by Email ( click here )
News | Home
CLARKSVILLE, Md., Nov. 4 MD-Neuronascent-ChemR

CLARKSVILLE, Md., Nov. 4 /PRNewswire/ -- Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Alzheimer's disease, Parkinson's and other neurodegenerative diseases, announces it has entered into a discovery agreement with ChemRar Pharma, a Russian biotechnology start-up company focusing on small-molecule modulators for developmental pathways and stem cells to treat cancer. Under the terms of the agreement, Neuronascent will screen certain ChemRar proprietary developmental pathway inhibitors utilizing their proprietary drug discovery platform for neurogenesis and neuroprotection. Financial terms of the collaboration were not disclosed.

The agreement matches ChemRar's discovery and translational research focus through scientific collaboration with Neuronascent's success in discovering novel, neurogenic and neuroprotective drug candidates. The companies intend to evaluate co-development opportunities for future commercialization and funding.

"We are proud to start this collaboration with ChemRar Pharma on these studies, highlighting our expertise in the field of neurogenesis, and look forward to the potential of this relationship," notes Dr. Judith Kelleher-Andersson, President and CSO, Neuronascent, Inc.

Nikolay Merkin, CBO of ChemRar Pharma, comments: "We are pleased that Neuronascent will bring high value to our R&D program and expand the scope of our molecules with their unique and well-established stem cell and neurogenesis platform. We look forward to achieving success in this collaboration."

About ChemRar Pharma:
ChemRar Pharma was established in 2007 in Moscow, Russia under the roof of the ChemRar High Tech Center as an innovative oncology start-up. In 2009, ChemRar in-licensed the portfolio of developmental pathway inhibitors from AllaChem and ChemDiv, Inc. (San Diego, CA) and established the R&D collaboration with ChemDiv's Chemical Diversity Research Institute in Moscow to continue preclinical and clinical development for multiple cancer indications.

About Neuronascent, Inc.:
Founded in 2004 by Dr. Judith Kelleher-Andersson, Neuronascent, Inc. discovers and develops first-in-class, small-molecule therapeutics, based on the science of neurogenesis, that target depression, neurodegenerative diseases, including Alzheimer's and Parkinson's, and Down syndrome. The Company is headquartered in Clarksville, MD and has facilities in Rockville and Walkersville, MD. For additional information, please visit www.neuronascent.com.

Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects" and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ moderately from current expectations.

SOURCE Neuronascent, Inc.


Copyright © 2008 PR Newswire. All rights reserved.

Share/Save/Bookmark

Article : Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News

Hormel Foods Increases Annual Dividend
AUSTIN, Minn. - The Board of Directors of Hormel Foods Corporation (NYSE: HRL), a multinational marketer of consumer-branded food and meat products, today announced its 44th consecutive annual dividend increase. The annual dividend on the common stock of the corpor

Research and Markets: Global Retail Trends 2009 – Q4 Update
DUBLIN - Research and Markets (

Advanced Explorations Expands Asian Business Network
TORONTO, ONTARIO -- 11/24/09 -- Advanced Explorations Inc. (the "Company" or "AEI") (TSX VENTURE: AXI)(FRANKFURT: AE6) is pleased to announce the appointment of Mr. Lei (Eric) Guo to its board of directors. Eric Guo is President of China Mining Fin..

Research and Markets: Review of Developments in the Mobile Messaging Market
DUBLIN - Research and Markets (

WSP Holdings Announces Third Quarter 2009 Results
WUXI, China, Nov. 24 /PRNewswire-Asia-FirstCall/ -- WSP Holdings Limited (NYSE: WH) ("WSP Holdings" or the "Company"), a leading Chinese manufacturer of API (American Petroleum Institute) and non-API seamless casing, tubing and drill p...

Retail Ventures, Inc. Reports Third Quarter Sales
COLUMBUS, Ohio, Nov. 24 -- Retail Ventures, Inc. (NYSE: RVI) announced today sales from continuing operations, which represents sales of DSW Inc. (NYSE: DSW) only, for the thirteen weeks ended October 31, 2009 increased 13.6% to $444.6 million from $391.4 million ...

Union Dental Reports a Record Profit for the 3rd Quarter
CORAL SPRINGS, FL -- 11/24/09 -- Union Dental Holdings, Inc. (PINKSHEETS: UDHI) -- http://www.uniondentalcorp.com/ir -- announced revenues today for the 3rd Quarter with record profits for both the 3..

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.